Tags

Type your tag names separated by a space and hit enter

Comparison of incidences of cardiovascular events among new users of different statins: a retrospective observational cohort study.
Curr Med Res Opin. 2009 Nov; 25(11):2621-9.CM

Abstract

OBJECTIVE

To compare incidences of cardiovascular disease (CVD) in general and myocardial infarction (MI) specifically between new users of different statins in daily practice.

DESIGN AND METHODOLOGY

Retrospective observational cohort study. Data were obtained from the PHARMO Record Linkage System; the PHARMO database contains pharmacy dispensing records of 3 million patients in the Netherlands registered with community pharmacies, linked to hospitalisation records. The participants were new statin users in the period 2000-2005, excluding patients hospitalised for CVD events in the year prior to start of statin use.

MAIN OUTCOME MEASURES

Adjusted hazard ratios of hospitalisations for CVD (including any type of ischemic heart disease, stroke, or revascularisation procedure) in general, or MI in particular, occurring during use of the initial statin within two years of start of therapy, comparing users of different statins.

RESULTS

The mean follow-up duration of 76,147 new statin users (14,530 pravastatin, 27,752 simvastatin, 25,777 atorvastatin, 8088 rosuvastatin) was 55 weeks. Incidence rates of CVD and MI per 100 person years ranged from 0.75 and 0.15 for rosuvastatin to 1.72 and 0.29 for pravastatin. Rosuvastatin users had a lower incidence rate of CVD compared to other statin users in general (28% lower), and simvastatin (29% lower) and pravastatin users (40% lower) in particular. The difference with atorvastatin was not statistically significant. Since this was not a prospective randomised study, there is the potential for unobserved risk factors to be responsible for some of the differences observed.

CONCLUSION

Compared to other statin users without recent prior cardiovascular events, the incidence of fatal and non-fatal CVD in this retrospective observational cohort study was 28% lower among rosuvastatin users.

Authors+Show Affiliations

PHARMO Institute, Utrecht, the Netherlands. edith.heintjes@pharmo.nlNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Evaluation Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19743959

Citation

Heintjes, Edith M., et al. "Comparison of Incidences of Cardiovascular Events Among New Users of Different Statins: a Retrospective Observational Cohort Study." Current Medical Research and Opinion, vol. 25, no. 11, 2009, pp. 2621-9.
Heintjes EM, Penning-van Beest FJ, Johansson S, et al. Comparison of incidences of cardiovascular events among new users of different statins: a retrospective observational cohort study. Curr Med Res Opin. 2009;25(11):2621-9.
Heintjes, E. M., Penning-van Beest, F. J., Johansson, S., Stalenhoef, A. F., & Herings, R. M. (2009). Comparison of incidences of cardiovascular events among new users of different statins: a retrospective observational cohort study. Current Medical Research and Opinion, 25(11), 2621-9. https://doi.org/10.1185/03007990903269112
Heintjes EM, et al. Comparison of Incidences of Cardiovascular Events Among New Users of Different Statins: a Retrospective Observational Cohort Study. Curr Med Res Opin. 2009;25(11):2621-9. PubMed PMID: 19743959.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Comparison of incidences of cardiovascular events among new users of different statins: a retrospective observational cohort study. AU - Heintjes,Edith M, AU - Penning-van Beest,Fernie J A, AU - Johansson,Saga, AU - Stalenhoef,Anton F, AU - Herings,Ron M C, PY - 2009/9/12/entrez PY - 2009/9/12/pubmed PY - 2009/12/30/medline SP - 2621 EP - 9 JF - Current medical research and opinion JO - Curr Med Res Opin VL - 25 IS - 11 N2 - OBJECTIVE: To compare incidences of cardiovascular disease (CVD) in general and myocardial infarction (MI) specifically between new users of different statins in daily practice. DESIGN AND METHODOLOGY: Retrospective observational cohort study. Data were obtained from the PHARMO Record Linkage System; the PHARMO database contains pharmacy dispensing records of 3 million patients in the Netherlands registered with community pharmacies, linked to hospitalisation records. The participants were new statin users in the period 2000-2005, excluding patients hospitalised for CVD events in the year prior to start of statin use. MAIN OUTCOME MEASURES: Adjusted hazard ratios of hospitalisations for CVD (including any type of ischemic heart disease, stroke, or revascularisation procedure) in general, or MI in particular, occurring during use of the initial statin within two years of start of therapy, comparing users of different statins. RESULTS: The mean follow-up duration of 76,147 new statin users (14,530 pravastatin, 27,752 simvastatin, 25,777 atorvastatin, 8088 rosuvastatin) was 55 weeks. Incidence rates of CVD and MI per 100 person years ranged from 0.75 and 0.15 for rosuvastatin to 1.72 and 0.29 for pravastatin. Rosuvastatin users had a lower incidence rate of CVD compared to other statin users in general (28% lower), and simvastatin (29% lower) and pravastatin users (40% lower) in particular. The difference with atorvastatin was not statistically significant. Since this was not a prospective randomised study, there is the potential for unobserved risk factors to be responsible for some of the differences observed. CONCLUSION: Compared to other statin users without recent prior cardiovascular events, the incidence of fatal and non-fatal CVD in this retrospective observational cohort study was 28% lower among rosuvastatin users. SN - 1473-4877 UR - https://www.unboundmedicine.com/medline/citation/19743959/Comparison_of_incidences_of_cardiovascular_events_among_new_users_of_different_statins:_a_retrospective_observational_cohort_study_ L2 - http://www.tandfonline.com/doi/full/10.1185/03007990903269112 DB - PRIME DP - Unbound Medicine ER -